ERBB3, IGF1R, and TGFBR2 expression correlate with PDGFR expression in glioblastoma and participate in PDGFR inhibitor resistance of glioblastoma cells

Kang Song; Ye Yuan; Yong Lin; Yan-Xia Wang; Jie Zhou; Qu-Jing Gai; Lin Zhang; Min Mao; Xiao-Xue Yao; Yan Qin; Hui-Min Lu; Xiang Zhang; You-Hong Cui; Xiu-Wu Bian; Xia Zhang; Yan Wang

ERBB3, IGF1R, and TGFBR2 expression correlate with PDGFR expression in glioblastoma and participate in PDGFR inhibitor resistance of glioblastoma cells

Am J Cancer Res. 2018 May 1;8(5):792-809. eCollection 2018.

Authors

Kang Song^{1

2}, Ye Yuan^{1

2}, Yong Lin^{1

2}, Yan-Xia Wang^{1

2}, Jie Zhou^{1

2}, Qu-Jing Gai^{1

2}, Lin Zhang^{1

2}, Min Mao^{1

2}, Xiao-Xue Yao^{1

2}, Yan Qin^{1

2}, Hui-Min Lu^{1

2}, Xiang Zhang^{1

2}, You-Hong Cui^{1

2}, Xiu-Wu Bian^{1

2}, Xia Zhang^{1

2}, Yan Wang^{1

2}

Affiliations

¹ Department of Pathology, Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University Chongqing 400038, China.
² Key Laboratory of Tumor Immunology and Pathology of Ministry of Education Chongqing 400038, China.

PMID: 29888103
PMCID: PMC5992513

Abstract

Glioma, the most prevalent malignancy in brain, is classified into four grades (I, II, III, and IV), and grade IV glioma is also known as glioblastoma multiforme (GBM). Aberrant activation of receptor tyrosine kinases (RTKs), including platelet-derived growth factor receptor (PDGFR), are frequently observed in glioma. Accumulating evidence suggests that PDGFR plays critical roles during glioma development and progression and is a promising drug target for GBM therapy. However, PDGFR inhibitor (PDGFRi) has failed in clinical trials, at least partially, due to the activation of other RTKs, which compensates for PDGFR inhibition and renders tumor cells resistance to PDGFRi. Therefore, identifying the RTKs responsible for PDGFRi resistance might provide new therapeutic targets to synergetically enhance the efficacy of PDGFRi. In this study, we analyzed the TCGA glioma database and found that the mRNA expressions of three RTKs, i.e. ERBB3, IGF1R, and TGFBR2, were positively correlated with that of PDGFR. Co-immunoprecipitation assay indicated novel interactions between the three RTKs and PDGFR in GBM cells. Moreover, concurrent expression of PDGFR with ERBB3, IGF1R, or TGFBR2 in GBM cells attenuated the toxicity of PDGFRi and maintained the activation of PDGFR downstream targets under the existence of PDGFRi. Thus, ERBB3, IGF1R, and TGFBR2 might participate in PDGFRi resistance of GBM cells. Consistent with this notion, combination of PDGFRi with inhibitor targeting either ERBB3 or IGF1R more potently suppressed the growth of GBM cells than each inhibitor alone. The positive correlations of PDGFR with ERBB3, IGF1R, and TGFBR2 were further confirmed in 66 GBM patient samples. Intriguingly, survival analysis showed that ERBB3 predicted poor prognosis in GBM patients with high PDGFRA expression. Altogether, our work herein suggested that ERBB3, IGF1R, and TGFBR2 were responsible for PDGFRi resistance and revealed that ERBB3 acted as potential prognostic marker and therapeutic target for GBM with high PDGFRA expression.

Keywords: ERBB3; Glioblastoma; IGF1R; PDGFR; TGFBR2; resistance.